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HIV-1 gene expression is activated via an interaction between the virally encoded Tat protein and a target RNA, TAR. 
TAR is located at the immediate 5' end of all viral mRNAs and comprises a partially base-paired stem with a tripyrimidine 
bulge in the upper stem and a hexanucleotide loop. In vitro, Tat binds specifically to the bulge and upper stem region with 
no requirement for the loop. In contrast, when Tat activation is analyzed in primate ceils, mutations in the loop abolish 
activation, suggesting a critical role for loop binding cellular factors. However, in rodent cells the reverse is true. Messages 
with a mutation in the TAR loop are activated whereas messages harboring a wild-type TAR sequence are not activated. 
By testing the effect of mutations in the bulge and stem in the context of mutation in the loop we now show that this loop- 
independent activation by Tat in rodent cells requires the critical bulge stem sequences needed for Tat binding in vitro. 
These data suggest that in rodent cells, as in vitro, Tat does not require a loop binding cofactor. In rodent cells containing 
human chromosome 12 (CHO12), however, Tat activation is both bulge and loop dependent. It appears that rodent cells, 
but not CliO12 cells, are refractory to the normal Tat/TAR activation pathway not by virtue of lacking a loop binding cofactor, 
but rather by the presence of a loop binding inhibitor of either Tat binding or the activation process. © 1995 Academic 
Press, leo. 
Tat stimulates HIV-1 gene expression by binding to 
the TAR sequence at the start of viral transcripts (1, 2). 
TAR is a partially base-paired s tem- loop  with a tripyri- 
midine bulge in the upper stem (3). In vitro binding stud- 
ies have shown that specific nucleotides in the bulge 
and upper stem are critical for Tat binding, but the loop 
sequence and structure is dispensable (4-6) .  In vivo, 
however, the loop sequences are critical as mutation 
abolishes activation (e.g., 7). This implies that TAR loop 
binding cellular factors have a key role in activation. 
However, Tat can also activate gene expression when 
tethered to a heterologous RNA binding protein (8, 9), or 
when tethered upstream via a DNA binding protein (10). 
This suggests that TAR per se is dispensable for activa- 
tion and serves only as the anchoring device to bring 
Tat to the promoter. Any TAR binding factors are therefore 
perhaps more likely to play a role in Tat location rather 
than as effectors of activation. There is genetic evidence 
to suggest that Tat might be unable to bind to TAR in 
vivo without a cooperative interaction with a loop binding 
cellular factor (11, 12). In contrast to this notion, two 
examples of Tat activation of messages containing a TAR 
loop mutant have been reported. First, in Xenopus oo- 
cytes, where Tat, atypically but specifically, activates 
translation of TAR RNA (13), a loop mutant target in ex- 
cess was activated. This activation was dependent upon 
the bulge and stem sequences of TAR, implying that Tat 
was binding directly at the classic binding site without 
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loop factors (14). Secondly, in rodent cells it has been 
shown that whereas wild-type TAR cannot be activated, 
a TAR loop mutant is activated (15). In the rodent system 
it is formally possible that Tat is functioning by a TAR 
independent pathway. It has been shown that Tat can 
activate the HIV LTR via NF-KB (16) and it can activate 
heterologous promoters such as CMVI-E (17, 18) and the 
JC virus late promoter (19). Also Tat activates the TNF-c~ 
gene via interacting with a "pseudo-TAR" sequence in the 
TNF-a transcript (20). In rodent cells containing human 
chromosome 12 (CHO12), Tat activation can be restored 
to levels that approach those obtained in human cells 
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FIG. 1. Structure of the expression pIasmids used for wild-type 
(pOGS210) and TAR mutants ($1 through $5). CAT, bacterial CAT cod- 
ing region; I, simian virus 40 small t-intron; pA, polyadenylation site. 
The TAR stem loop is represented by arrows and the bulge and loop 
features are marked. The plasmid pPE511 has been described (13). 
Plasmids pPE682, pPE685, pSA160, and pSA151 were made by either 
PCR or oligonucleotide substitution mutagenesis using standard tech- 
niques (27). The sequences of the mutated TAR elements are indicated. 
Mutated residues are underlined; dashes indicate a deletion. 
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FIG. 2. Tat activation of wild-type and loop mutant TAR in CHO and CHO12 cells. Transient ransfections were carried out by calcium phosphate 
coprecipitation onto subconfluent OHO cells (A) or 0HO12 cells (B). Extracts were assayed after 48 hr for CAT activity using QuainT-CAT, a 
scintillation counting based assay (Amersham International plc.). Transfection efficiency was determined by cotransfection of 250 ng of human 
cytomegalovirus promoter driven luciferase piasmid (pMW41; M. White and S. M. Kingsman, unpublished results) and luciferase assays were carried 
cut as described (28). Plasmids encoding wildqype (X) or loop mutant $1 (O) TAR RNA (2 #g each) were transfected into CHO cells or CHO12 cells 
with 0-1 #g of pOGS213 and 250 ng of pMW41. Protein extracts containing an equal number of luciferase units were assayed for CAT activity. 
and this has been interpreted as suggesting that human 
chromosome 12 may encode a coactivator protein(s) nec- 
essary for the activation process (15, 25, 26). In the pres- 
ent study we have analyzed TAR- loop  independent acti- 
vation in both CHO and CHO12 cells to determine 
whether the sequence requirements for Tat binding, as 
defined in vitro are preserved in these in vivo systems. 
Our data show that in rodent cells, Tat activation is still 
dependent upon the bulge region but TAR loop binding 
proteins are not an essential requirement for Tat activa- 
tion. In contrast, the introduction of human chromosome 
12 creates a cellular environment where the loop se- 
quence is once again critical for Tat action which is itself 
still dependent upon the bulge. 
The wild-type HIV LTR was fused to the bacterial chlor- 
amphenicol  acetyl transferase (CAT) reporter gene to 
produce plasmid pOGS210 (21). Derivatives of pOGS210, 
containing specific mutations in the TAR element, were 
constructed (Fig. 1). The mutations comprised a three 
base substitution of the sequence 30/CUGGG/34 to 30/ 
AGGGU/34 in the loop (pPE511;S 1), a substitution of U23 
to C23 in the bulge (pPE682;S2), a 3 base deletion of the 
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FIG. 3. The effect of mutations in the TAR bulge and stem on Tat activation in Hela (A), CHO (B), and CHO12 (C) cells• Plasmids were transfected 
at a ratio of 500 ng of template (TAR) to 10 ng of pOGS213 (Tat) into Hela cells, at a ratio of 2 #g of template to 500 ng of pOGS213 into CHO 
cells, or at a ratio of 2 #g of template to 100 ng of pOGS213 together with the transfection control plasmid pMW41• CAT activity was assayed as 
above. RNA was prepared using Ultraspec RNA (AMS Biotechnology) and was analyzed by primer extension. The primer used for primer extension 
analysis of CAT RNA was as described (23) and corresponded to nucleotides +33 to +13 in the CAT gene, and the primer used for analysis of 
Tat RNA corresponded to nucleotides +50 to +30 (21). The extension products are indicated. 
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bulge (pPE685;S3), and two double mutations that had 
the loop mutation $1 and either the bulge substitution 
mutation $2 (pSA150;S4) or an upper stem substitution of 
A27=U38 to U27=A38 (pSA151;S 5). All of these mutations 
result in a marked reduction in Tat activation in Heia 
cells (4, 22, 23). 
We first wished to establish the kinetics of Tat activa- 
tion of wild-type and loop mutant TAR in both CHO and 
0HO12 cells. Template DNAs were cotransfected with 
increasing amounts of the Tat expressing plasmid 
pOGS213 (21) into OHO or 0HO12 cells and extracts 
were assayed for CAT activity after 48 hr (Fig. 2). As 
observed previously in CHO cells (15), the loop-mutated 
TAR was activated by about 20-fold (Fig. 2A.), whereas, in 
comparison, activation of wild-type TAR was significantly 
reduced. We have also observed similar levels of activa- 
tion of a loop-mutated TAR in NiH3T3 cells (data not 
shown)• This degree of activation was clearly significant, 
but it required 500-1000 ng of the Tat expression plas- 
mid compared to the 1-10 ng required to achieve maxi- 
mum activation in Hela cells (23). The requirement for 
increased Tat may be due to different levels of expres- 
sion of Tat, or it may suggest that the kinetics of activation 
are different in the two systems. In CHO12 cells the wild- 
type TAR was activated approximately 19-fold whereas 
the loop mutated TAR, as in HeLa cells, showed a much 
reduced level of activation (Fig. 2B). The patterns of acti- 
vation of the two templates were ssentially reversed in 
the two cell types despite the condition of template and 
Tat being the same. 
We next tested whether the loop independent activa- 
tion observed in CHO cells and loop dependent activa- 
tion in CHO12 cells required specific nucleotides in the 
bulge and upper stem. Wild-type and mutant TAR plas- 
mids were cotransfected with pOGS213 into HeLa cells, 
CHO cells, or CHO12 cells and extracts were analyzed 
for CAT activity and CAT RNA after 48 hr (Fig. 3). To 
control for the sensitivity of the enzyme and RNA detec- 
tion the HeLa cell transfection conditions were adjusted 
to give an activation of wild-type TAR comparable to that 
obtained with the loop-mutated TAR in CHO cells. The 
data confirm the phenotypes of bulge and loop mutants 
in Hela cells (Fig. 3A). In the CHO cells wild type (lanes 
1 and 2), bulge mutant $2 (lanes 5 and 6), and bulge 
mutant $3 (lanes 7 and 8) were inactive (Fig. 3B), The 
loop mutated TAR ($1) showed significant activation 
when both RNA and protein were measured (lanes 3 and 
4), suggesting that the mechanism of activation in CHO 
cells was transcriptional rather than post-transcriptional. 
In contrast, the loop mutants with second site mutations 
in either the bulge, $4 (lanes 9 and 10), or the upper 
stem $5 (lanes 11 and 12) showed no significant activa- 
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tion. These data indicate that the loop independent acti- 
vation in CHO cells is still TAR specific. In 0HO12 cells, 
however, as in HeLa cells the wild-type TAR was signifi- 
cantly activated by Tat (Fig. 30, compare lanes 1 and 2) 
whereas activation of the loop-mutated TAR was much 
reduced (lanes 3 and 4) to levels similar to those ob- 
tained in HeLa cells (compare Fig. 3A, lanes 3 and 4, 
with Fig. 30, lanes 3 and 4). We considered the possibility 
that the different phenotypes of Tat activation in CHO 
and 0HO12 cells might somehow be due to differences 
in the expression of Tat produced in the tWO cell types. 
The expression levels were equivalent in both cell types 
and were within fourfold for all the mutant combinations 
tested (Figs. 3B and 30). In CHO cells we have shown 
that two bases defined in vitro as important for Tat bind- 
ing are required for the activation and this suggests that 
Tat is interacting with the same binding site in vivo. The 
simplest interpretation of the data is, therefore, that in 
CHO cells under conditions of high Tat and high tem- 
plate, Tat can bind directly to TAR in the absence of any 
loop binding cellular factor. The finding that an appar- 
ently "classical" Tat activation pathway can operate in 
CHO cells is consistent with the previous observations 
that Tat can activate expression in CHO cells if tethered 
to the RNA via a heterologous RNA binding protein (24). 
This indicates that any other cellular factors in the path- 
way are not limiting. In CHO12 cells, however, activation 
is dependent on both the bulge and the loop of TAR as 
activation of a loop mutated TAR is much reduced. 
It is at present difficult to explain the difference in 
behavior between wild-type and loop mutated TAR RNAs 
in CHO and 0HO12 cells. The simplest interpretation is 
that CHO cells contain a specific TAR loop binding pro- 
tein that inhibits Tat action. Our data may also suggest 
that in CHO12 cells human chromosome 12 encodes a 
further inhibitor of loop-independent activation. However, 
other studies have indicated that the defect in Tat activa- 
tion in CHO cells is a loss of function, as human chromo- 
some 12 and to a lesser extent human chromosome 6 
can complement the defect (15, 25, 26). One would have 
to propose that additional loop binding human cell fac- 
tors displace the CHO cell inhibitor. 
In summary, we have shown that loop independent 
activation in CHO cells is still dependent upon the spe- 
cific Tat binding nucleotides in the bulge and upper stem. 
This suggests that a loop binding cofactor is not obliga- 
tory for Tat binding or activation in vivo. 
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